Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
Go back to Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 217.05 -0.1 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $217.15 | 52 Week High | $333.65 | |||
| Open | $221.00 | 52 Week Low | $223.02 | |||
| Day High | $222.25 | P/E | 27.79 | |||
| Day Low | $215.56 | EPS | $7.81 | |||
| Volume | 74,193 | |||||
| (NASDAQ: STOK) | Delayed: 29.10 +0.07 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.03 | 52 Week High | $ | |||
| Open | $29.38 | 52 Week Low | $ | |||
| Day High | $29.59 | P/E | N/A | |||
| Day Low | $29.01 | EPS | $ | |||
| Volume | 61,537 | |||||
